- Fourth-quarter revenue of $0.73 million, up 64% year-over-year – - Full-year revenue of $3.11 million, up 148% year-over-year –…
The new version 5.0 of the AI model EDEN™ features a novel toxin antigen predictor, is trained on an expanded…
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by…
SAN DIEGO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform…
- New U.S. patent covers the design and composition of the BVP - - Positive results from ongoing preclinical studies…
Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort Combination…
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-beingNEW YORK, Sept. 19, 2024 (GLOBE…
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused…
BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…
Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA…